Dashboard
Manage Tickers

GOSSGossamer Bio, Inc.

Nasdaq gossamerbio.com


$ 0.93 $ 0.02 (2.2 %)    

Monday, 09-Sep-2024 15:59:41 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 0.93
$ 0.94
$ 0.93 x 682
-- x --
$ 0.90 - $ 0.97
$ 0.45 - $ 1.60
540,530
na
210.39M
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-17-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-03-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-26-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 03-24-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 03-22-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Goss...
08/30/2024 09:42:41

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

gossamer-bio-announced-two-oral-presentations-and-poster-presentation-with-data-relevant-to-seralutinib-at-european-respiratory-society-congress-2024
Gossamer Bio Announced Two Oral Presentati...
08/26/2024 20:02:53

- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna -

wedbush-reiterates-outperform-on-gossamer-bio-maintains-4-price-target
Wedbush Reiterates Outperform on Gossamer ...
08/13/2024 12:29:59

Wedbush analyst Laura Chico reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $4 price target.

gossamer-bio-q2-2024-gaap-eps-022-beats-016-estimate-sales-95842m-miss-114286m-estimate
Gossamer Bio Q2 2024 GAAP EPS $0.22 Beats ...
08/12/2024 20:04:39

Gossamer Bio (NASDAQ:GOSS) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.16 by...

gossamer-bios-clean-safety-profile-differentiates-it-from-merck-analyst-says
Gossamer Bio's Clean Safety Profile Differ...
06/25/2024 18:39:14

Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary art...

gossamer-bio-and-2-other-stocks-under-2-insiders-are-buying
Gossamer Bio And 2 Other Stocks Under $2 I...
06/25/2024 12:51:30

oppenheimer-initiates-coverage-on-gossamer-bio-with-outperform-rating-announces-price-target-of-9
Oppenheimer Initiates Coverage On Gossamer...
06/25/2024 09:40:52

Oppenheimer analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announce...

why-kaival-brands-innovations-shares-are-trading-lower-by-47-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Kaival Brands Innovations Shares Are T...
06/21/2024 18:04:00

goldman-sachs-maintains-buy-on-gossamer-bio-maintains-8-price-target
Goldman Sachs Maintains Buy on Gossamer Bi...
06/17/2024 16:45:34

Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $8 price target.

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
06/11/2024 20:31:35

hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Goss...
05/20/2024 15:10:24

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

gossamer-bio-provides-updated-seralutinib-torrey-open-label-extension-data-at-the-american-thoracic-society-2024-international-conference-which-takes-place-may-17-22
Gossamer Bio Provides Updated Seralutinib ...
05/14/2024 20:15:56

Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization o...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
05/13/2024 20:31:07

wedbush-reiterates-outperform-on-gossamer-bio-maintains-4-price-target
Wedbush Reiterates Outperform on Gossamer ...
05/08/2024 14:19:14

Wedbush analyst Laura Chico reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $4 price target.

gossamer-bio-q1-eps-019-misses-018-estimate
Gossamer Bio Q1 EPS $(0.19) Misses $(0.18)...
05/07/2024 20:48:04

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18...

gossamer-bio-collaborates-with-italian-drugmaker-chiesi-to-advance-lung-health-solutions-worldwide
Gossamer Bio Collaborates With Italian Dru...
05/06/2024 17:17:19

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hyperte...

hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Goss...
05/06/2024 16:16:31

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

watching-gossamer-bio-traders-circulate-unconfirmed-analyst-comments-suggesting-partnership-with-chiesi-group-is-a-major-win-for-seralutinib-development-partnership-further-increases-pos-for-the-development-of-seralutinib-as-a-best-in-class-therapeutic-reiterates-buy-rating-and-15-pt
Watching Gossamer Bio; Traders Circulate U...
05/06/2024 14:40:28

trading-halt-halt-status-updated-at-75500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:55:...
05/06/2024 11:55:07

gossamer-bio-secures-160m-partnership-with-chiesi-group-to-accelerate-development-of-pulmonary-hypertension-treatment-486m-potential-for-seralutinib-collaboration
Gossamer Bio Secures $160M Partnership wit...
05/06/2024 11:37:40

Gossamer Bio, Inc. ("Gossamer") (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development an...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION